5 results about "Jnk inhibitor" patented technology

Provided is an isolated human naive pluripotent stem cell (PSC), wherein: (i) when the naive PSC is a female PSC, then said naive female PSC has two unmethylated alleles of an X-inactive specific transcript (XIST) gene; and (ii) when said naive PSC is a male PSC, then said naive male PSC has an unmethylated allele of said XIST gene. Also provided is a culture medium which comprises an ERK1 / 2 inhibitor, a GSK3beta inhibitor, a p38 inhibitor, a JNK inhibitor, a STAT3 activator and at least one agent selected from the group consisting of: bFGF, TGFbeta 1, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor; or at least agent selected from the group consisting of: a TGFR inhibitor, a FGFR inhibitor, a PKC inhibitor, a ROCK inhibitor and a NOTCH inhibitor.

This document describes methods for increasing the sensitivity of a cancer cell to alternating electric fields, comprising exposing the cancer cell to an alternating electric field for a specified period of time, said alternating electric field having a specified frequency and field strength, and exposing the cancer cell to an IGFR1 inhibitor, a JNK inhibitor, an RPS6 inhibitor, or an ERK inhibitor. It also describes methods for increasing the efficacy of the treatment, comprising applying an alternating electric field to a target site on the subject for a specified period of time, said alternating electric field having a specified frequency and field strength, wherein the target site comprises one or more cancer cells, and administering to the subject a therapeutically effective amount of one or more inhibitors of IGF1R, JNK, RPS6, and / or ERK.Methods for treating a subject with cancer are described, comprising applying an alternating electric field to a target site of the subject for a period of time, said alternating electric field having a determined frequency and field strength, wherein the target site comprises one or more cancer cells, and administering a therapeutically effective amount of one or more inhibitors of IGF1R, JNK, RPS6, and / or ERK to the subject. Methods for reducing the viability of cancer cells using an alternating electric field for a period of time, said alternating electric field having a determined frequency and field strength, in combination with an inhibitor of IGF1R, JNK, RPS6, and / or ERK, are described.Methods for increasing apoptosis of a cancer cell are described comprising exposing the cancer cell to an alternating electric field for a period of time, said alternating electric field having a determined frequency and field intensity; and exposing the cancer cell to an inhibitor of IGFR1, JNK, RPS6 or ERK.

The application discloses a medicine composition and pharmaceutical use of a combination of a JNK inhibitor and a PARG inhibitor. The application discloses for the first time that the JNK inhibitor (such as BIRB 796) and the PARG inhibitor (such as PDD00017273) can improve the synergistic effect of treating gastric cancer, the two inhibitors have a synergistic effect when used in combination, have a synergistic effect, realize a significant improvement of an anti-tumor effect, and do not increase the toxicity to various organs by the combination, but rather reduce the dosage of various drugs, thereby reducing the side effects, and have a significant significance for the application of the combination of the PARG inhibitor and the JNK inhibitor to the treatment of gastric cancer.

The invention discloses a pharmaceutical composition of JNK inhibitor and PARG inhibitor combined medication and pharmaceutical application. The invention discloses for the first time that the JNK inhibitor (such as bentamamol) and the PARG inhibitor (such as PDD00017273) have the synergistic effect on improving the gastric cancer treatment effect, the two inhibitors have the synergistic effect when being combined for use, the anti-tumor effect is remarkably improved, toxicity to each organ is not increased through combined use, and the effect of treating the gastric cancer can be obviously improved through combined use of the JNK inhibitor (such as bentamamol) and the PARG inhibitor (such as PDD00017273). On the contrary, the dosage of various medicines is reduced, so that the toxic and side effects are reduced, and the obvious significance is realized on the gastric cancer resisting application of PARG inhibitor and JNK inhibitor combined medication.